series-b
Stage
2
Investors
About
Atavistik Bio is a clinical-stage biotechnology company developing selective allosteric small-molecule therapeutics targeting disease-causing proteins, with lead programs for Hereditary Hemorrhagic Telangiectasia and myeloproliferative neoplasms.
Explore Atavistik Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.